Podcasts

Episode 63 | Dr Megan Sanders: From Science to TOGA Leadership

In this episode, we welcome Dr Megan Sanders, CEO of the Thoracic Oncology Group of Australasia.

Episode Summary

In this episode of Conversations in Lung Cancer Research, host A/Prof Mel Moore interviews Dr Megan Sanders, the Chief Executive Officer of TOGA.

They discuss Megan’s journey from working in vaccine formulation to earning a PhD in immunology, working in clinical trials, and eventually leading TOGA. They explore the challenges and achievements of TOGA, the importance of multidisciplinary engagement in lung cancer treatment, and the organisation’s strategic plan for strengthening research and membership engagement.

The conversation touches on the potential of clinical quality registries to improve patient care and highlights the ongoing effort to address the gaps in funding and equitable care for lung cancer patients.

Show Links

Play Episode 63 | Dr Megan Sanders: From Science to TOGA Leadership

More Podcasts

75 – The Evolving Landscape of ROS1-positive NSCLC

Podcasts
September 4, 2026

Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong,

74 – Prof Zarnie Lwin OAM: Mentorship, Research, and the Future of Lung Cancer Treatment

Podcasts
August 28, 2026

Host A/Prof Mel Moore interviews Prof Zarnie Lwin OAM, University of Queensland; Medical Oncologist at Royal Brisbane and Women’s Hospital and The Prince Charles Hospital.

73 – Smoking Stigma and Lung Cancer Care in the Screening Era

Podcasts
August 14, 2026

A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer.

72 – Dr Jazmin Eckhaus: Robotic Innovations and Ethics in Thoracic Surgery

Podcasts
July 31, 2026

Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.

71 – Immunotherapy in Thoracic Cancers: Applying Broad IO Access Across Thoracic Malignancies

Podcasts
June 26, 2026

Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.

70 – Immunotherapy in Thoracic Cancers: From Indication-Based to Biology-Driven

Podcasts
June 19, 2026

Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.